Vertex Pharmaceuticals price to free cash flow VRTX
Market value divided by free cash flow over the last twelve months, since 2012.
- Today, Nov 3, 2026
- n/m
- a quarter missing
- 10-year median
- 32.5×
- 10-year range
- 16.0× to 164×
- Peer median
- 20.9×
Vertex Pharmaceuticals' price to free cash flow can't be checked today: its free cash flow for Q3 FY26, the quarter to Sep 30, 2026, is missing from our data, so the twelve months it rests on can't be added up.
On the days it had one over the last ten years, its median was 32.5×, from 16.0× in Jun 2021 to 164× in Apr 2017.
Price to free cash flow over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 36.9× | 29.4× | 39.5× |
| 2025 | 35.2× | 26.9× | 35.2× |
| 2024 | 34.3× | 25.5× | 34.4× |
| 2023 | 24.9× | 18.8× | 25.2× |
| 2022 | 19.4× | 19.0× | 32.2× |
| 2021 | 29.1× | 16.0× | 29.6× |
| 2020 | 20.6× | 18.8× | 46.9× |
| 2019 | 41.7× | 30.3× | 46.9× |
| 2018 | 38.9× | 37.7× | 64.4× |
| 2017 | 54.9× | 51.6× | 164× |
| 2016 | n/m a value too high to mean anything | ||
| 2015 | n/m a value too high to mean anything | ||
| 2014 | n/m a value too high to mean anything | ||
| 2013 | 150× | 14.5× | 167× |
| 2012 | 13.1× | 12.4× | 82.8× |
Against its peers
Companies in Biotechnology nearest Vertex Pharmaceuticals' size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| VRTXVertex Pharmaceuticals | n/m |
| REGNRegeneron Pharmaceuticals | 26.6× |
| ONCBeOne Medicines | 30.2× |
| UTHRUnited Therapeutics | 23.7× |
| INCYIncyte | 12.7× |
| ALNYAlnylam Pharmaceuticals | 26.7× |
| EXELExelixis | 14.8× |
| NBIXNeurocrine Biosciences | 17.0× |
| HALOHalozyme Therapeutics | 18.2× |
| Peer median | 20.9× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Vertex Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.